GUJARAT TERCE LABORATORIES LTD.

Gujarat Terce Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from July 1, 2026, and will continue until 48 hours after the declaration of the company's unaudited financial results for the first quarter ending June 30, 2026. The trading window will reopen once the mandatory closure period concludes. The date of the board meeting to consider these financial results will be communicated separately.

Gujarat Terce Laboratories Ltd has amended its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, in compliance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended code incorporates recent amendments to the SEBI regulations and is available on the company's website.

Gujarat Terce Laboratories Ltd has announced that its 41st Annual General Meeting (AGM) will be held on Friday, August 21, 2026. The decision was made during a Board of Directors meeting on May 29, 2026. The cut-off date for determining members' eligibility for e-voting and participation in the AGM is August 14, 2026. This disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gujarat Terce Laboratories Ltd announced audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 29, 2026. The company's revenue from operations for FY26 stood at ₹47.81 Cr. The audit report, issued by Shah Doshi Patel & Associates LLP, has an unmodified opinion. The company operates in the pharmaceutical segment.

Gujarat Terce Laboratories Ltd has re-appointed Mr. Aalap Prajapati as the Managing Director & CEO for a term of 5 years, effective from October 28, 2026, to October 27, 2031. This decision, based on the Nomination and Remuneration Committee's recommendations, was approved by the Board of Directors on May 29, 2026, and is subject to shareholder approval at the upcoming 41st Annual General Meeting. Mr. Prajapati has over 15 years of experience in the pharmaceutical sector.

Gujarat Terce Laboratories Ltd's board approved the annual audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The statutory auditor, Shah Doshi Patel & Associates LLP, issued an unmodified opinion on the results. Revenue from operations for the year ended March 31, 2026, stood at ₹4747.27 Lakhs. Total revenue reached ₹4781.31 Lakhs. Profit before tax was ₹303.23 Lakhs. The company operates in the pharmaceutical segment.

Gujarat Terce Laboratories Ltd announced audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 29, 2026. The company's revenue from operations for FY26 stood at ₹47.81 Cr. The audit report, issued by Shah Doshi Patel & Associates LLP, had an unmodified opinion. The board meeting commenced at 3:00 p.m. (IST) and concluded at 8:31 p.m. (IST).

Gujarat Terce Laboratories Ltd has rescheduled its board meeting, originally slated for May 27, 2026, to May 29, 2026, due to unavoidable circumstances. The meeting will consider and approve the audited standalone financial results for the fourth quarter and year ended March 31, 2026.

Gujarat Terce Laboratories Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the Annual Audited Standalone Financial Results for the fourth quarter and financial year ended March 31, 2026. The board will also consider matters related to the upcoming Annual General Meeting. The trading window has been closed from April 1, 2026, to May 29, 2026, for consideration of the financial results.

Gujarat Terce Laboratories Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct. The closure will be effective from 1 April 2026 until the end of forty-eight hours after the declaration of the Audited Financial Results for the quarter and financial year ending on 31 March 2026. The reopening of the trading window will occur after the mandatory period of window closure. The date of the Board Meeting for considering the Audited Financial Results will be intimated in due course.